Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents (original) (raw)
Impact of direct-acting antivirals on the recurrence of hepatocellular carcinoma in chronic hepatitis C
Hepatoma Research
Hepatoma Research, 2022
View PDFchevron_right
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis
Daniele Nicolini
Digestive and Liver Disease
View PDFchevron_right
HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: still an issue?
Hepatoma Research
Hepatoma Research, 2018
View PDFchevron_right
Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?
Giuseppe Cabibbo
Expert Review of Anticancer Therapy, 2018
View PDFchevron_right
Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review
Mohamed El-Kassas
Journal of Advanced Research, 2019
View PDFchevron_right
De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus
Mohamed Nabil
European journal of gastroenterology & hepatology, 2017
View PDFchevron_right
Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals
xavier adhoute
European Journal of Gastroenterology & Hepatology, 2018
View PDFchevron_right
Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals
Javid Fazili
Cureus, 2018
View PDFchevron_right
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
fabio fucilli
World journal of gastroenterology, 2018
View PDFchevron_right
Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment
Kazuhiro Nouso, Hepatoma Research
Hepatoma Research, 2019
View PDFchevron_right
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort
Odile Goria
Clinics and Research in Hepatology and Gastroenterology, 2020
View PDFchevron_right
Direct-acting antivirals and hepatocellular carcinoma recurrence
Ahmed Abdel-Razik
Journal of Public Health and Emergency, 2021
View PDFchevron_right
The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C
Hepatoma Research
Hepatoma Research, 2020
View PDFchevron_right
Impact of direct-acting antivirals on de novo occurrence of hepatocellular carcinoma in hepatitis C virus patients
Ming Yang, Hepatoma Research
Hepatoma Research, 2020
View PDFchevron_right
Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis
Mohamed El-Kassas
Journal of viral hepatitis, 2017
View PDFchevron_right
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals
Maciej Jablkowski
Liver Cancer, 2018
View PDFchevron_right
Decreased risk of hepatocellular carcinoma recurrence with directacting antivirals compared with no treatment for hepatitis C: a meta-analysis
Alex Duong
Annals of Gastroenterology
View PDFchevron_right
The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study
Darrick Li
Hepatology (Baltimore, Md.), 2017
View PDFchevron_right
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C
Joseph koffi DOKPO
Liver international : official journal of the International Association for the Study of the Liver, 2017
View PDFchevron_right
Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment – preliminary report
Dariusz Wasiak
Clinical and Experimental Hepatology
View PDFchevron_right
Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis
Leonardo Frazzoni
Journal of Clinical Medicine, 2021
View PDFchevron_right
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma
George Ioannou
Journal of hepatology, 2017
View PDFchevron_right
The impact of direct-acting antivirals on hepatitis C associated hepatocellular carcinoma
Tai-Ping Lee, Hepatoma Research
Hepatoma Research, 2020
View PDFchevron_right
Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal
Ioannis Tsomidis, Elias Kouroumalis, Hepatoma Research
Hepatoma Research, 2023
View PDFchevron_right
Frequency of De Novo Hepatocellular Carcinoma after Direct-acting Antiviral Therapy for Chronic Hepatitis C: A Prospective Follow-up
Aneeqa Ahmad
Euroasian Journal of Hepato-Gastroenterology
View PDFchevron_right
Risk of De Novo Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C
Samuel Antwi
Cancer Prevention Research, 2019
View PDFchevron_right
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study
Irene Cacciola
Alimentary pharmacology & therapeutics, 2017
View PDFchevron_right
The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma
Loreto Boix
Liver international : official journal of the International Association for the Study of the Liver, 2017
View PDFchevron_right